Addition of sotatercept to existing therapy shows promise for the treatment of pulmonary arterial hypertension

Sotatercept cuts death, clinical worsening by 84% in pulmonary arterial hypertension

NEW ORLEANS — Sotatercept, a novel activin signaling inhibitor, reduced risk for death and clinical worsening by 84% in patients with pulmonary arterial hypertension compared with placebo, according to results of the STELLAR trial. “I am convinced that this is going to be a paradigm shift in the way we treat pulmonary hypertension patients,” Marius M. Hoeper, MD, deputy director

Addition of sotatercept to existing therapy shows promise for the treatment of pulmonary arterial hypertension

Patients with pulmonary arterial hypertension (PAH), a severe, progressive condition that affects the heart and lungs, who were treated with the novel first-in-class medication sotatercept on top of existing therapy experienced significant improvements in walking distance via a six-minute walking test—the study's primary endpoint and a validated surrogate for functional improvement and reduced symptom burden.